Problems in serum albumin measurement and clinical significance of albumin microheterogeneity in cirrhotics

Nutrition

Volumn 20, Issue 4, 2004, Pages 351-357

  Watanabe, Akiharu ^a   Matsuzaki, Shohei ^b   Moriwaki, Hisataka ^b   Suzuki, Kazuyuki ^b   Nishiguchi, Shuhei ^b  

^a UNIVERSITY OF TOYAMA   (Japan)

^b NONE

Author keywords

Advanced glycation end products; Glycoalbumin; Liver disease; Oxidized albumin; Serum protein

Indexed keywords

ALBUMIN; BROMCRESOL PURPLE; BROMOCRESOL GREEN; SERUM ALBUMIN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CELL HETEROGENEITY; CONTROLLED STUDY; DISEASE COURSE; DYE DILUTION CURVE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOALBUMINEMIA; IMMUNOASSAY; INTERMETHOD COMPARISON; LABORATORY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; UNIVERSITY HOSPITAL;

AGED; BROMCRESOL GREEN; BROMCRESOL PURPLE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; IMMUNOASSAY; INDICATORS AND REAGENTS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PROGNOSIS; SERUM ALBUMIN;

EID: 1642276935     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nut.2003.12.006     Document Type: Article

References (49)

1. Watson D. Albumin and "total globulin" fraction of blood. Adv Clin Chem. 8:1965;237.
2. Rosenoer V.M., Oratz M., Rothschild M.A. Albumin structure, function and uses. 1977;Pergamon, Elmsford.
3. Doweiko J.P., Nompleggi D.J. The role of albumin in human physiology and pathophysiology, part III albumin and disease states. JPEN. 15:1991;212.
4. Skrede S., Blomhoff J.P., Elgjo K., Gjone E. Serum proteins in diseases of the liver. Scand J Clin Lab Invest. 35:1975;399.
5. Muto Y., Yoshida T., Sato S., et al. Effect of oral administration of branched-chain amino acid granules (BCAA-G) in patients with liver cirrhosis a clinical study. (in Japanese) JPEN. 11:1989;1119.
6. Muto Y., Yoshida T., Sato S., et al. Effect of oral administration of branched-chain amino acid granules (BCAA-G) in patients with liver cirrhosis a double blind study. (in Japanese) JPEN. 11:1989;1137.
7. Muto Y., Yoshida T., Sato S., Suzuki K., Watanabe A. Effect of oral supplementation with BCAA-G on the prognosis of liver cirrhosis. (ion Japanese) JPEN. 14:1992;765.
8. Muto Y., Yoshida T., Kato M., et al. Serum albumin level and prognosis in patients with liver cirrhosis - result of branched-chain amino acid granules (BCAA-G) supplement trial. (in Japanese) JPEN. 17:1995;1135.
9. Japan Society of Clinical Examination Technologists. Investigative report of accuracy management (Heisei 9th year) (in Japanese). Kosei Company, Ltd., Tokyo, 1997:66.
10. Child C.G. III, Trucotte J.G. Surgery and portal hypertension. Child C.G. III. The liver and portal hypertension. 3rd ed :1964;90 WB Saunders, Philadelphia.
11. Rodkey F.L. Direct spectrophotometric determination of albumin in human serum. Clin Chem. 11:1965;478.
12. Era S., Kuwata K., Imai H., et al. Age-related change in redox state of human serum albumin. Biochim Biophys Acta. 1247:1995;12.
13. Era S., Hamaguchi T., Sogami M., et al. Further studies on the resolution of human mercapt- and nonmercaptalbumin and on human serum albumin in the elderly by high-performance liquid chromatography. Int J Pept Protein Res. 31:1988;435.
14. Ziyadeh F.N., Cohen M.P. Effects of glycated albumin on mesangial cells evidence for a role in diabetic nephropathy. Mol Cell Biochem. 125:1993;19.
15. Association of Clinical Biochemists Ltd. News Sheet No. 186, October 1978.
16. Daumas B.T., Watson A., Biggs H.G. Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta. 31:1971;87.
17. Okamoto K. Quantitative method for serum albumin concentration by using bromcresol purple. (in Japanese) J Med Technol. 18:1974;646.
18. Sogami M., Era S. HPLC-studies on nonmercapt-mercapt conversion of human serum albumin. Int J Peptide Res. 25:1985;398.
19. Shima K., Itoh N. High-performance liquid chromatography assay of serum glycated albumin. Diabetologia. 31:1988;627.
20. Pinnell A.E., Northam B.E. New automated dyebinding method for serum albumin determination with bromcresol purple. Clin Chem. 24:1978;80.
21. Schmidt Von H, Ebeling H, Kraft D. Vergleiche konventioneller methoden zur albumin-, transferrin- und coeruloplasmin- bestimmung in serum mit immunologischen referenzmethoden. Z Klin Chem Klin Biochem 1975;13:117.
22. Javed M.U., Waqua S.N. An enzymatic method for the detection of human serum albumin. Exp Mol Med. 33:2001;103.
23. Ihara H., Nakamura H., Aoki Y., Aoki T., Yoshida M. Effects of serum-isolated vs synthetic bilirubin-albumin complexes on dye-binding methods for estimating serum albumin. Clin Chem. 37:1991;1269.
24. Mabuchi H., Nakahashi H. Underestimation of serum albumin by the bromcresol purple method and a major endogenous ligand in uremia. Clin Chim Acta. 37:1987;89.
25. Muramoto Y., Kushigemachi A., Matsushita M., Irino T. Increase in albumin concentration measured by bromcresol purple method during storage of serum. (in Japanese with English abstract) Jpn J Clin Chem. 20:1991;13.
26. Muramoto Y., Matsushita M., Irino T. Reduction of reaction differences between human mercaptalbumin and human nonmercaptalbumin measured by the bromcresol purple method. Clin Chim Acta. 289:1999;69.
27. Muramoto Y., Sasaki M., Aoki Y., Matsushita M. Evaluation of a new routine method for the determination of serum albumin with bromcresol purple. (in Japanese with English abstract) Med Exam. 46:1997;823.
28. Peters T. Jr. Clinical aspects: albumin in medicine. Peters T. Jr. All about albumin. 1996;251 Academic Press, New York.
29. Moriwaki H., Tajika M., Miwa Y. Protein-energy malnutrition, glucose intolerance. (in Japanese) Acta Hepatol Jpn. 43:2002;101.
30. Kuroki T., Nishiguchi S., Nakajima S., et al. The management of nutrition for hepatic cirrhosis. (in Japanese with English abstract) Jpn J Clin Med. 52:1994;197.
31. Kuwata K., Era S., Sogami M. The kinetic studies on the intramolecular SH, S-S exchange reaction of bovine mercaptalbumin. Biochim Biophys Acta. 1205:1994;317.
32. Sogami M., Era S., Nagaoka S., et al. High-performance liquid chromatographic studies on non-mercapt in equilibrium with mercapt conversion of human serum albumin. II. J Chromtogr. 332:1985;19.
33. Suzuki E., Yasuda K., Takeda N., et al. Increased oxidized form of human serum albumin in patients with diabetes mellitus. Diabetes Res Clin Pract. 18:1992;153.
34. Yasukawa K. Glycation and oxidation of albumin. (in Japanese) Clin Med Technol. 44:2000;907.
35. Kadota K., Yui Y., Hattori R., Murohara Y., Kawai C. Decreased sulfhydryl groups of serum albumin in coronary artery disease. Jpn Circ J. 55:1991;937.
36. Murohara Y., Yui Y., Hattori R., Kadota K., Kawai C. Human serum albumin inhibits prostacyclin production by endothelial cells the relation of the inhibitory activity to sulfhydryl groups in albumin. Jpn Circ J. 55:1991;777.
37. Lapolla A., Fedele D., Seraglia R., et al. A new effective method for the evaluation of glycated intact plasma proteins in diabetic subjects. Diabetologia. 38:1995;1076.
38. Lapolla A., Fedele D., Seraglia R., et al. A new effective method for the evaluation of glycated intact plasma proteins in diabetic subjects. Diabetologia. 38:1995;1076.
39. Dobrian A., Simionescu M. Irreversibly glycated albumin alters the physico-chemical characteristics of low density lipoproteins of normal and diabetic subjects. Biochim Biophys Acta. 1270:1995;26.
40. Shaklai N., Garlick R.L., Bunn H.F. Nonenzymatic glycosylation of human serum albumin alters its conformation and function. J Biol Chem. 259:1984;3812.
41. 131I-tagged albumin. J Clin Invest. 30:1951;1238.
42. Horiuchi S. The liver is the main site for metabolism of circulating advanced glycation endproducts. J Hepatol. 36:1951;123.
43. Thornalley PJ. The clinical significance of glycation. Clin Lab 1999;45:263.
44. Thornalley P.J., Langborg A., Minhas H.S. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J. 344:1999;109.
45. Sebekov K, Kupcov V, Schinzel R, Heidland A. Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis-amelioration by liver transplantation. J Hepatol 2002;36:66.
46. Smith P.R., Thornalley P.J. Mechanism of the degradation of non-enzymatically glycated proteins under physiological conditions. Studies with the model fructosamine, Nε-(1-deoxy-D-fructos-1-yl) hippuryl-lysine. Eur J Biochem. 210:1992;729.
47. Chen S., Cohen M.P., Ziyadeh F.N. Amadori-glycated albumin in diabetic nephropathy pathophysiologic connections. Kidney Int. 58:(suppl 77):2000;S40.
48. Schalkwijk C.G., Ligtvoet N., Twaalhoven H., et al. Amadori albumin in type I diabetic patients correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries. Diabetes. 48:1999;2446.
49. Cohen M.P., Ziyadeh F.N. Role of Amadori-modified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy. J Am Soc Nephrol. 7:1996;183.